Drug Trial Radar · NCT04901689
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
316
Planned (sponsor's estimate)
Start
Oct 23, 2021
Primary completion
Feb 2023
Study completion Feb 2023
Sponsor
- Lead sponsor
- Hospital Israelita Albert EinsteinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CytoDyn, Inc.
- First posted
- May 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19). The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring mechanical ventilation or extracorporeal oxigenation (ECMO).
Conditions
- COVID-19 Pneumonia
Interventions
LeronlimabDrug
Leronlimab 700 mg
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative proportion of clinical recoveryTime frame: 28 days
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Hospital Israelita Albert Einstein
São Paulo, Brazil
Hospital M'Boi Mirim
São Paulo, Brazil
Hospital Dr Jayme dos Santos Neves
Laranjeiras, Espírito Santo, Brazil
Clinica São Roque
Ipiaú, Estado de Bahia, Brazil
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel
Salvador, Estado de Bahia, Brazil
Hospital do Coração do Brasil
Brasília, Federal District, Brazil
Santa Casa de Misericórdia de Passos
Passos, Minas Gerais, Brazil
Hospital 9 de Julho
São Paulo, Please Select, Brazil
Hospital São Lucas Copacabana
Rio de Janeiro, Rio de Janeiro, Brazil
Instituto Atena de Pesquisa Clínica
Natal, Rio Grande do Norte, Brazil
Hospital São Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital Mãe de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Fundação PIO XII
Barretos, São Paulo, Brazil
Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista
Bragança Paulista, São Paulo, Brazil
Instituto de Pesquisa Clínica de Campinas
Campinas, São Paulo, Brazil
Hospital Santa Ignes
Indaiatuba, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, Brazil
BP Mirante
São Paulo, São Paulo, Brazil
Hospital Alemão Oswaldo Cruz
São Paulo, São Paulo, Brazil
Hospital Beneficência Portuguesa
São Paulo, São Paulo, Brazil
Santa Casa de Votuporanga
Votuporanga, São Paulo, Brazil
Centro de Pesquisa Clínica do Coração
Aracaju, Sergipe, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.